Group One Trading, L.P. Ocuphire Pharma, Inc. Transaction History

Group One Trading, L.P.

$3.01 Billion
Q2 2024

A detailed history of Group One Trading, L.P. transactions in Ocuphire Pharma, Inc. stock. As of the latest transaction made, Group One Trading, L.P. holds 76 shares of OCUP stock, worth $105. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Holding current value

$105

% of portfolio

0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.51 - $2.23 $114 - $169	76 New	76 $0
Q4 2023 Feb 14, 2024	SELL	$2.59 - $3.64 $4,115 - $5,783	-1,589 Reduced 69.18%	708 $2,000
Q3 2023 Nov 09, 2023	BUY	$3.35 - $4.33 $7,694 - $9,946	2,297 New	2,297 $7,000
Q1 2023 May 12, 2023	SELL	$3.01 - $3.85 $10,267 - $13,132	-3,411 Reduced 70.16%	1,451 $5,000
Q4 2022 Feb 09, 2023	BUY	$2.04 - $3.53 $9,918 - $17,162	4,862 New	4,862 $17,000
Q1 2022 May 12, 2022	SELL	$2.75 - $4.39 $2,172 - $3,468	-790 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$3.4 - $5.19 $104,866 - $160,075	-30,843 Reduced 97.5%	790 $3,000
Q3 2021 Nov 12, 2021	BUY	$3.84 - $5.38 $44,759 - $62,709	11,656 Added 58.35%	31,633 $163,000
Q2 2021 Aug 10, 2021	BUY	$4.24 - $6.57 $84,702 - $131,248	19,977 New	19,977 $105,000

Others Institutions Holding OCUP

# of Institutions

Shares Held

2.74M

Call Options Held

Put Options Held

Vanguard Group Inc Valley Forge, PA

992K
Shares

$1.38 Million
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

266K
Shares

$369,537
0.0% of portfolio
Rice Hall James & Associates, LLC

224K
Shares

$310,788
0.02% of portfolio
Richmond Brothers, Inc. Jackson, MI

191K
Shares

$265,912
0.6% of portfolio
Bridgeway Capital Management, LLC Houston, TX

164K
Shares

$227,599
0.01% of portfolio

View Full List

About Ocuphire Pharma, Inc.

Ticker OCUP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,579,800
Market Cap $28.6M
Description
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...

More about OCUP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.

Account